Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone

Ben M. Tsai, Meijing Wang, Jeffrey M. Pitcher, Ajay Kher, Paul Crisostomo, Daniel R. Meldrum

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Hypoxic pulmonary vasoconstriction is a challenging clinical problem with limited therapeutic options. Milrinone, a phosphodiesterase (PDE)-3 inhibitor, is frequently used to treat perioperative pulmonary hypertension. However, recent evidence suggests that the PDE-5 isoform may be more specific for lung tissue. We hypothesized that the PDE-5 inhibitor zaprinast has greater efficacy for pulmonary vasorelaxation, attenuation of hypoxic pulmonary vasoconstriction, and inhibition of hypoxia-induced pulmonary artery cytokine expression when compared with milrinone. To study this, isolated rat pulmonary artery and thoracic aorta rings suspended in physiologic organ baths for measurement of isometric force transduction were treated with vehicle (dimethyl sulfoxide), milrinone, or zaprinast to assess pulmonary artery relaxation, thoracic aorta relaxation, inhibition of hypoxic (pO2 = 30-35 mmHg) pulmonary vasoconstriction, and hypoxia-induced pulmonary artery TNF-α and IL-1β expression (reverse transcriptase-PCR). Milrinone and zaprinast resulted in dose-dependent pulmonary artery and aortic relaxation, but zaprinast caused significantly less aortic relaxation compared with milrinone (50.12% ± 3.36% versus 91.03% ± 2.97%, P < 0.001). Zaprinast, but not milrinone, significantly inhibited hypoxic pulmonary vasoconstriction (zaprinast, 58.42% ± 5.37%; milrinone, 77.65% ± 4.42% versus vehicle: 74.42% ± 7.54%). Hypoxia-induced upregulation of TNF-α and IL-1β mRNA in pulmonary artery was decreased by zaprinast, but not milrinone, pretreatment. These results suggest that zaprinast, but not milrinone, preferentially vasodilates pulmonary artery over aorta, attenuates hypoxic pulmonary vasoconstriction, and inhibits hypoxia-induced pulmonary artery TNF-α and IL-1β expression. Therefore, PDE-5 inhibition may be advantageous in the treatment of pulmonary hypertension.

Original languageEnglish
Pages (from-to)417-420
Number of pages4
JournalShock
Volume24
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Milrinone
Lung Injury
Pulmonary Artery
Vasoconstriction
Lung
Interleukin-1
Type 5 Cyclic Nucleotide Phosphodiesterases
Thoracic Aorta
Pulmonary Hypertension
Phosphodiesterase 3 Inhibitors
zaprinast
Phosphodiesterase 5 Inhibitors
Dimethyl Sulfoxide
Reverse Transcriptase Polymerase Chain Reaction
Baths
Vasodilation
Aorta
Protein Isoforms
Up-Regulation
Cytokines

Keywords

  • Hypoxia
  • Inflammation
  • Phosphodiesterase
  • Pulmonary hypertension
  • Vascular tone

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Physiology

Cite this

Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. / Tsai, Ben M.; Wang, Meijing; Pitcher, Jeffrey M.; Kher, Ajay; Crisostomo, Paul; Meldrum, Daniel R.

In: Shock, Vol. 24, No. 5, 11.2005, p. 417-420.

Research output: Contribution to journalArticle

Tsai, Ben M. ; Wang, Meijing ; Pitcher, Jeffrey M. ; Kher, Ajay ; Crisostomo, Paul ; Meldrum, Daniel R. / Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. In: Shock. 2005 ; Vol. 24, No. 5. pp. 417-420.
@article{2bdd6e31935a4dbcac8572a944268f04,
title = "Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone",
abstract = "Hypoxic pulmonary vasoconstriction is a challenging clinical problem with limited therapeutic options. Milrinone, a phosphodiesterase (PDE)-3 inhibitor, is frequently used to treat perioperative pulmonary hypertension. However, recent evidence suggests that the PDE-5 isoform may be more specific for lung tissue. We hypothesized that the PDE-5 inhibitor zaprinast has greater efficacy for pulmonary vasorelaxation, attenuation of hypoxic pulmonary vasoconstriction, and inhibition of hypoxia-induced pulmonary artery cytokine expression when compared with milrinone. To study this, isolated rat pulmonary artery and thoracic aorta rings suspended in physiologic organ baths for measurement of isometric force transduction were treated with vehicle (dimethyl sulfoxide), milrinone, or zaprinast to assess pulmonary artery relaxation, thoracic aorta relaxation, inhibition of hypoxic (pO2 = 30-35 mmHg) pulmonary vasoconstriction, and hypoxia-induced pulmonary artery TNF-α and IL-1β expression (reverse transcriptase-PCR). Milrinone and zaprinast resulted in dose-dependent pulmonary artery and aortic relaxation, but zaprinast caused significantly less aortic relaxation compared with milrinone (50.12{\%} ± 3.36{\%} versus 91.03{\%} ± 2.97{\%}, P < 0.001). Zaprinast, but not milrinone, significantly inhibited hypoxic pulmonary vasoconstriction (zaprinast, 58.42{\%} ± 5.37{\%}; milrinone, 77.65{\%} ± 4.42{\%} versus vehicle: 74.42{\%} ± 7.54{\%}). Hypoxia-induced upregulation of TNF-α and IL-1β mRNA in pulmonary artery was decreased by zaprinast, but not milrinone, pretreatment. These results suggest that zaprinast, but not milrinone, preferentially vasodilates pulmonary artery over aorta, attenuates hypoxic pulmonary vasoconstriction, and inhibits hypoxia-induced pulmonary artery TNF-α and IL-1β expression. Therefore, PDE-5 inhibition may be advantageous in the treatment of pulmonary hypertension.",
keywords = "Hypoxia, Inflammation, Phosphodiesterase, Pulmonary hypertension, Vascular tone",
author = "Tsai, {Ben M.} and Meijing Wang and Pitcher, {Jeffrey M.} and Ajay Kher and Paul Crisostomo and Meldrum, {Daniel R.}",
year = "2005",
month = "11",
doi = "10.1097/01.shk.0000183390.98519.05",
language = "English",
volume = "24",
pages = "417--420",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone

AU - Tsai, Ben M.

AU - Wang, Meijing

AU - Pitcher, Jeffrey M.

AU - Kher, Ajay

AU - Crisostomo, Paul

AU - Meldrum, Daniel R.

PY - 2005/11

Y1 - 2005/11

N2 - Hypoxic pulmonary vasoconstriction is a challenging clinical problem with limited therapeutic options. Milrinone, a phosphodiesterase (PDE)-3 inhibitor, is frequently used to treat perioperative pulmonary hypertension. However, recent evidence suggests that the PDE-5 isoform may be more specific for lung tissue. We hypothesized that the PDE-5 inhibitor zaprinast has greater efficacy for pulmonary vasorelaxation, attenuation of hypoxic pulmonary vasoconstriction, and inhibition of hypoxia-induced pulmonary artery cytokine expression when compared with milrinone. To study this, isolated rat pulmonary artery and thoracic aorta rings suspended in physiologic organ baths for measurement of isometric force transduction were treated with vehicle (dimethyl sulfoxide), milrinone, or zaprinast to assess pulmonary artery relaxation, thoracic aorta relaxation, inhibition of hypoxic (pO2 = 30-35 mmHg) pulmonary vasoconstriction, and hypoxia-induced pulmonary artery TNF-α and IL-1β expression (reverse transcriptase-PCR). Milrinone and zaprinast resulted in dose-dependent pulmonary artery and aortic relaxation, but zaprinast caused significantly less aortic relaxation compared with milrinone (50.12% ± 3.36% versus 91.03% ± 2.97%, P < 0.001). Zaprinast, but not milrinone, significantly inhibited hypoxic pulmonary vasoconstriction (zaprinast, 58.42% ± 5.37%; milrinone, 77.65% ± 4.42% versus vehicle: 74.42% ± 7.54%). Hypoxia-induced upregulation of TNF-α and IL-1β mRNA in pulmonary artery was decreased by zaprinast, but not milrinone, pretreatment. These results suggest that zaprinast, but not milrinone, preferentially vasodilates pulmonary artery over aorta, attenuates hypoxic pulmonary vasoconstriction, and inhibits hypoxia-induced pulmonary artery TNF-α and IL-1β expression. Therefore, PDE-5 inhibition may be advantageous in the treatment of pulmonary hypertension.

AB - Hypoxic pulmonary vasoconstriction is a challenging clinical problem with limited therapeutic options. Milrinone, a phosphodiesterase (PDE)-3 inhibitor, is frequently used to treat perioperative pulmonary hypertension. However, recent evidence suggests that the PDE-5 isoform may be more specific for lung tissue. We hypothesized that the PDE-5 inhibitor zaprinast has greater efficacy for pulmonary vasorelaxation, attenuation of hypoxic pulmonary vasoconstriction, and inhibition of hypoxia-induced pulmonary artery cytokine expression when compared with milrinone. To study this, isolated rat pulmonary artery and thoracic aorta rings suspended in physiologic organ baths for measurement of isometric force transduction were treated with vehicle (dimethyl sulfoxide), milrinone, or zaprinast to assess pulmonary artery relaxation, thoracic aorta relaxation, inhibition of hypoxic (pO2 = 30-35 mmHg) pulmonary vasoconstriction, and hypoxia-induced pulmonary artery TNF-α and IL-1β expression (reverse transcriptase-PCR). Milrinone and zaprinast resulted in dose-dependent pulmonary artery and aortic relaxation, but zaprinast caused significantly less aortic relaxation compared with milrinone (50.12% ± 3.36% versus 91.03% ± 2.97%, P < 0.001). Zaprinast, but not milrinone, significantly inhibited hypoxic pulmonary vasoconstriction (zaprinast, 58.42% ± 5.37%; milrinone, 77.65% ± 4.42% versus vehicle: 74.42% ± 7.54%). Hypoxia-induced upregulation of TNF-α and IL-1β mRNA in pulmonary artery was decreased by zaprinast, but not milrinone, pretreatment. These results suggest that zaprinast, but not milrinone, preferentially vasodilates pulmonary artery over aorta, attenuates hypoxic pulmonary vasoconstriction, and inhibits hypoxia-induced pulmonary artery TNF-α and IL-1β expression. Therefore, PDE-5 inhibition may be advantageous in the treatment of pulmonary hypertension.

KW - Hypoxia

KW - Inflammation

KW - Phosphodiesterase

KW - Pulmonary hypertension

KW - Vascular tone

UR - http://www.scopus.com/inward/record.url?scp=27644464325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644464325&partnerID=8YFLogxK

U2 - 10.1097/01.shk.0000183390.98519.05

DO - 10.1097/01.shk.0000183390.98519.05

M3 - Article

C2 - 16247326

AN - SCOPUS:27644464325

VL - 24

SP - 417

EP - 420

JO - Shock

JF - Shock

SN - 1073-2322

IS - 5

ER -